Discontinued — last reported Q2 '25
Business Segments · Total segment depreciation and amortization
U.S. Pharmaceutical — Total segment depreciation and amortization
McKesson U.S. Pharmaceutical — Total segment depreciation and amortization increased by 5.0% to $63.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric grew by 5.0%, from $60.00M to $63.00M. Over 2 years (FY 2021 to FY 2023), U.S. Pharmaceutical — Total segment depreciation and amortization shows relatively stable performance with a 0.2% CAGR.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2019
Last reportedQ2 2025
Rolls up toD&A
How to read this metric
High levels indicate significant investment in infrastructure or acquired intangible assets like customer relationships.
Detailed definition
The non-cash expense allocated to the U.S. Pharmaceutical segment for the wear and tear of physical assets and the amort...
Peer comparison
Standard accounting metric for capital-intensive distribution businesses.
Metric ID:
mck_segment_u_s_pharmaceutical_total_segment_depreciation_and_amortizationHistorical Data
13 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '24 | Q2 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $52.75M | $52.75M | $52.75M | $57.00M | $57.00M | $57.00M | $57.00M | $53.00M | $53.00M | $53.00M | $53.00M | $60.00M | $63.00M |
| QoQ Change | — | +0.0% | +0.0% | +8.1% | +0.0% | +0.0% | +0.0% | -7.0% | +0.0% | +0.0% | +0.0% | +13.2% | +5.0% |
| YoY Change | — | — | — | — | +8.1% | +8.1% | +8.1% | -7.0% | -7.0% | -7.0% | -7.0% | +13.2% | +5.0% |
Range$52.75M – $63.00M
CAGR+6.1%
Avg YoY Growth+1.6%
Median YoY Growth+5.0%
Current Streak5 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — total segment depreciation and amortization?
- McKesson (MCK) reported u.s. pharmaceutical — total segment depreciation and amortization of $63.00M in Q2 2025.
- How has McKesson's u.s. pharmaceutical — total segment depreciation and amortization changed year-over-year?
- McKesson's u.s. pharmaceutical — total segment depreciation and amortization increased by 5.0% year-over-year, from $60.00M to $63.00M.
- What is the long-term trend for McKesson's u.s. pharmaceutical — total segment depreciation and amortization?
- Over 2 years (2021 to 2023), McKesson's u.s. pharmaceutical — total segment depreciation and amortization has grown at a 0.2% compound annual growth rate (CAGR), from $211.00M to $212.00M.
- What does u.s. pharmaceutical — total segment depreciation and amortization mean?
- The non-cash cost of using up physical and intangible assets within the segment.